These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35189779)

  • 1. Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2.
    Deepthi V; Mohanakumar KP; Rajamma U
    J Biomol Struct Dyn; 2023 Apr; 41(7):2911-2925. PubMed ID: 35189779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetracycline as an inhibitor to the SARS-CoV-2.
    Zhao TY; Patankar NA
    J Cell Biochem; 2021 Jul; 122(7):752-759. PubMed ID: 33619758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
    Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; Brás NF; Jha HC
    J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
    Jena AB; Kanungo N; Nayak V; Chainy GBN; Dandapat J
    Sci Rep; 2021 Jan; 11(1):2043. PubMed ID: 33479401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing immune boosting and anti-viral efficacy of
    Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
    J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urtica dioica Agglutinin: A plant protein candidate for inhibition of SARS-COV-2 receptor-binding domain for control of Covid19 Infection.
    Sabzian-Molaei F; Nasiri Khalili MA; Sabzian-Molaei M; Shahsavarani H; Fattah Pour A; Molaei Rad A; Hadi A
    PLoS One; 2022; 17(7):e0268156. PubMed ID: 35901082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors.
    Singh R; Bhardwaj VK; Sharma J; Kumar D; Purohit R
    Comput Biol Med; 2021 Sep; 136():104631. PubMed ID: 34273770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D3 and its hydroxyderivatives as promising drugs against COVID-19: a computational study.
    Song Y; Qayyum S; Greer RA; Slominski RM; Raman C; Slominski AT; Song Y
    J Biomol Struct Dyn; 2022; 40(22):11594-11610. PubMed ID: 34415218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes.
    Dutta S; Panthi B; Chandra A
    J Phys Chem B; 2022 Jul; 126(29):5375-5389. PubMed ID: 35833966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
    Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
    J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An
    Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
    J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
    Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
    Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.
    Patil S; Alzahrani KJ; Banjer HJ; Halawani IF; Alzahrani H; Altayar MA; Albogami S; Angeles RF; Hassan AAA; Bhandi S; Raj AT
    J Infect Public Health; 2022 Jul; 15(7):781-787. PubMed ID: 35738053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
    Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
    J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
    Basit A; Ali T; Rehman SU
    J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.